Latest market price
38.90
-0.01-0.03%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -1.85 | Insider Own | — | Shs Outstand | 107.59M | Perf Week | -1.04% |
| Market Cap | 4.19B | Forward P/E | — | EPS next Y | -1.64 | Insider Trans | -0.50% | Shs Float | 81.92M | Perf Month | -3.90% |
| Enterprise Value | 3.73B | PEG | — | EPS next Q | -0.53 | Short Float | 14.35% | Perf Quarter | 1.35% | ||
| Income | -197.00M | P/S | — | EPS this Y | — | Short Ratio | 8.52 | Perf Half Y | 27.08% | ||
| Sales | 0.00 | P/B | 9.34 | EPS next Y | — | ROA | -41.11% | Short Interest | 11.75M | Perf YTD | 56.73% |
| Book/sh | 4.16 | P/C | 9.08 | EPS next 5Y | — | ROE | -39.01% | 52W High | 48.51 -19.81% | Perf Year | 138.21% |
| Cash/sh | 4.28 | P/FCF | — | EPS past 3/5Y | — | ROIC | -48.46% | 52W Low | 16.33 138.21% | Perf 3Y | 478.01% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 4.72% 4.51% | Perf 5Y | 132.93% |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 1.89 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 16.24 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 45.70 | Recom | 2.18 |
| Dividend Gr. 3/5Y | — | Current Ratio | 16.24 | EPS Q/Q | -55.88% | SMA20 | -0.12% | Beta | 0.38 | Target Price | 53.10 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | — | SMA50 | -5.90% | Rel Volume | 0.66 | Prev Close | 38.91 |
| Employees | 127 | LT Debt/Eq | 0.01 | Earnings | Nov 05 | SMA200 | 7.24% | Avg Volume | 1.47M | Price | 38.90 |
| IPO Date | Mar 26, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -13.32% — | Net Debt/EBITDA | — | Volume | 967,477 | Change | -0.03% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-21-26 | Reiterated | HC Wainwright & Co. | Buy | $45 → $57 |
| Aug-11-26 | Reiterated | Goldman Sachs | Neutral | $32 → $36 |
| Jul-20-26 | Reiterated | Evercore ISI Group | Outperform | $45 → $55 |
| Jul-09-26 | Initiated | Oppenheimer | Outperform | $51 |
| Jul-06-26 | Reiterated | Guggenheim | Buy | $51 |
| Jun-17-26 | Reiterated | RBC Capital | Outperform | $48 → $59 |
| Jun-17-26 | Reiterated | Goldman Sachs | Neutral | $20 → $32 |
| Jun-16-26 | Reiterated | Leerink Partners | $50 → $52 | |
| Jun-02-26 | Reiterated | RBC Capital | Outperform | $42 → $48 |
| Jun-02-26 | Reiterated | HC Wainwright & Co. | Buy | $45 |
Latest News· Times ET
Oct-27-26
Oct-27-2611:53AM
Oct-21-26
Oct-21-2612:30PM
Oct-14-26
Oct-14-2610:11PM
Oct-08-26
Oct-08-2608:00AM
Oct-02-26
Oct-02-2611:11PM
Oct-01-26
Oct-01-2608:00AM
Sep-25-26
Sep-25-2601:42PM
Sep-22-26
Sep-22-2606:29PM
07:00AM
Sep-18-26
Sep-16-26
Sep-11-26
Sep-11-2603:39AM
Sep-02-26
08:00AM
Aug-24-26
Company
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1 | 2 | 0 | 0 | — | — | — | — | |
| Gross Profit | -1 | -2 | 0 | 0 | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 46 | 40 | 32 | 23 | — | — | — | — | |
| Research and Development | 172 | 151 | 127 | 91 | — | — | — | — | |
| Other Operating Expense | 1 | -2 | 0 | 0 | — | — | — | — | |
| Operating Income | -219 | -191 | -159 | -114 | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 22 | 24 | 25 | 14 | — | — | — | — | |
| Net Income Before Taxes | -197 | -168 | -134 | -100 | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | |
| Consolidated Net Income | -197 | -168 | -134 | -100 | — | — | — | — | |
| Net Income From Continuing Operations | -197 | -168 | -134 | -100 | — | — | — | — | |
| Net Income | -197 | -168 | -134 | -100 | — | — | — | — | |
| EPS (Recurring) | -1.85 | -1.63 | -1.45 | -1.57 | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.85 | -1.63 | -1.45 | -1.57 | — | — | — | — | |
| EPS (Diluted) | -1.85 | -1.63 | -1.45 | -1.57 | — | — | — | — | |
| EBITDA | -195 | -166 | -132 | -98 | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 108 | 103 | 92 | 64 | — | — | — | — | |
| Market Capitalization | 4,201 | 2,556 | 2,456 | 700 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Donovan Joanne M. | CMO | Aug 13 '26 | Sale | 43.41 | 2,919 | 126,704 | 8,625 | Aug 14 |
| Donovan Joanne M. | CMO | Aug 12 '26 | Sale | 43.85 | 6,522 | 286,000 | 11,544 | Aug 14 |
| Donovan Joanne M. | CMO | Aug 12 '26 | Option Exercise | 0.00 | 12,812 | 0 | 18,066 | Aug 14 |
| Russell Alan J | Chief Scientific Officer | Aug 12 '26 | Option Exercise | 0.00 | 12,812 | 0 | 37,367 | Aug 14 |
| Russell Alan J | Chief Scientific Officer | Aug 12 '26 | Sale | 43.73 | 5,901 | 258,042 | 31,466 | Aug 14 |
| MOORE JOHN R | General Counsel | Aug 12 '26 | Option Exercise | 0.00 | 12,499 | 0 | 22,713 | Aug 14 |
| MOORE JOHN R | General Counsel | Aug 12 '26 | Sale | 43.82 | 5,016 | 219,823 | 17,697 | Aug 14 |
| Derakhshan Behrad | Chief Business Officer | Aug 12 '26 | Sale | 43.81 | 5,100 | 223,424 | 31,826 | Aug 14 |
| Derakhshan Behrad | Chief Business Officer | Aug 12 '26 | Option Exercise | 0.00 | 13,281 | 0 | 36,926 | Aug 14 |
| KOCH KEVIN | President and CEO | Aug 12 '26 | Option Exercise | 0.00 | 39,844 | 0 | 70,459 | Aug 14 |
| KOCH KEVIN | President and CEO | Aug 12 '26 | Sale | 43.68 | 17,971 | 785,042 | 52,488 | Aug 14 |
| Russell Alan J | Chief Scientific Officer | Jul 01 '26 | Option Exercise | 0.36 | 200,000 | 71,195 | 224,555 | Jul 02 |
| Russell Alan J | Chief Scientific Officer | Jul 01 '26 | Sale | 39.41 | 200,000 | 7,881,402 | 24,555 | Jul 02 |
| Donovan Joanne M. | CMO | May 05 '26 | Option Exercise | 7.08 | 50,000 | 354,000 | 54,367 | May 05 |
| Donovan Joanne M. | CMO | May 05 '26 | Sale | 38.57 | 50,000 | 1,928,400 | 4,367 | May 05 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.